142 related articles for article (PubMed ID: 18559974)
41. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis.
Vercauteren E; Gils A; Declerck PJ
Semin Thromb Hemost; 2013 Jun; 39(4):365-72. PubMed ID: 23457049
[TBL] [Abstract][Full Text] [Related]
42. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
43. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor.
Buelens K; Hillmayer K; Compernolle G; Declerck PJ; Gils A
Circ Res; 2008 Feb; 102(3):295-301. PubMed ID: 18063813
[TBL] [Abstract][Full Text] [Related]
44. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.
Schneider M; Nagashima M; Knappe S; Zhao L; Morser J; Nesheim M
J Biol Chem; 2002 Mar; 277(12):9944-51. PubMed ID: 11786552
[TBL] [Abstract][Full Text] [Related]
45. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
46. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
47. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
Bouma BN; Marx PF; Mosnier LO; Meijers JC
Thromb Res; 2001 Mar; 101(5):329-54. PubMed ID: 11297751
[TBL] [Abstract][Full Text] [Related]
48. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI).
Barbosa Pereira PJ; Segura-Martín S; Oliva B; Ferrer-Orta C; Avilés FX; Coll M; Gomis-Rüth FX; Vendrell J
J Mol Biol; 2002 Aug; 321(3):537-47. PubMed ID: 12162965
[TBL] [Abstract][Full Text] [Related]
49. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor.
Mao SS; Colussi D; Bailey CM; Bosserman M; Burlein C; Gardell SJ; Carroll SS
Anal Biochem; 2003 Aug; 319(1):159-70. PubMed ID: 12842119
[TBL] [Abstract][Full Text] [Related]
50. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms.
Mishra N; Vercauteren E; Develter J; Bammens R; Declerck PJ; Gils A
Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309
[TBL] [Abstract][Full Text] [Related]
51. Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B.
Valls Serón M; Plug T; Marquart JA; Marx PF; Herwald H; de Groot PG; Meijers JC
Thromb Haemost; 2011 Oct; 106(4):609-16. PubMed ID: 21800008
[TBL] [Abstract][Full Text] [Related]
52. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
53. Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
Park R; Song J; An SS
Korean J Hematol; 2010 Dec; 45(4):264-8. PubMed ID: 21253429
[TBL] [Abstract][Full Text] [Related]
54. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY
Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323
[TBL] [Abstract][Full Text] [Related]
55. Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo application.
Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
J Thromb Haemost; 2014 Feb; 12(2):229-36. PubMed ID: 24354544
[TBL] [Abstract][Full Text] [Related]
56. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism.
Colucci M; Binetti BM; Tripodi A; Chantarangkul V; Semeraro N
Blood; 2004 Mar; 103(6):2157-61. PubMed ID: 14630828
[TBL] [Abstract][Full Text] [Related]
57. Identification and characterization of two thrombin-activatable fibrinolysis inhibitor isoforms.
Zhao L; Morser J; Bajzar L; Nesheim M; Nagashima M
Thromb Haemost; 1998 Dec; 80(6):949-55. PubMed ID: 9869166
[TBL] [Abstract][Full Text] [Related]
58. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
[TBL] [Abstract][Full Text] [Related]
59. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
[TBL] [Abstract][Full Text] [Related]
60. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders.
Boffa MB; Nesheim ME; Koschinsky ML
Curr Drug Targets Cardiovasc Haematol Disord; 2001 Dec; 1(2):59-74. PubMed ID: 12769657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
